SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (2686)9/30/1997 3:54:00 AM
From: Henry Niman   of 9719
 
biowa, Not only can multiple drugs be used to hit weak spots in tumors, but they can also be used to enhance natural molecular relationships. A good example is the synergy seen with rexinoids and TZDs. Rexinoids activate RXRs which are natural partners for a variety of hormone receptors which are activated by various hormones. For overcoming insulin resistance, RXRalpha (activated by rexinoids such as Targretin and ALRT268) partners with PPARgamma (activated by TZDs such as Rezulin, BRL49653, or Pioglitizone). In mouse models of type II diabetes and obesity, the two receptor activators work best in combination. Moreover, a similar result was seen when treating a liposarcoma in culture (synergistic anti-tumor result). Not only does this combination produce a synergistic effect, but I think that such combos will allow each drug to be used a lower doses, reducing side effects and increasing specificity.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News